French-Belgian exchange on voluntary return

Fedasil | October 14, 2016

French-Belgian exchange on voluntary return
Fedasil and the OFII (Office français de l’Immigration et de l’Intégration) organised an exchange to share their expertise on voluntary return. The main focus was on the return counselling and the interviews with asylum seekers and irregular migrants.

Spotlight

The Hamilton Project seeks to advance America’s promise of opportunity, prosperity, and growth. We believe that today’s increasingly competitive global economy demands public policy ideas commensurate with the challenges of the 21st Century. The Project’s economic strategy reflects a judgment that long-term prosperity is best achieved by fostering economic growth and broad participation in that growth, by enhancing individual economic security, and by embracing a role for effective government in making needed public investments.


Other News
GOVERNMENT BUSINESS

Valneva and Scottish Enterprise in Advanced Discussions for Major Grant to Complete Livingston Site

Valneva | December 24, 2021

Valneva SE , a specialty vaccine company, today announced that it is in advanced discussions, with Scottish Enterprise, for a multi-million pound grant which will enable it to fully complete its strategic manufacturing site in Livingston, Scotland. Following the termination of the supply agreement with the UK Government (HMG) for Valneva’s inactivated COVID-19 vaccine candidate, VLA2001, Valneva paused its site plans. Valneva and Scottish Enterprise have since engaged in a highly constructive dialogue, and under the proposed grant, the Livingston site will be fully developed as a key vaccine production site for the long term. Both Valneva and Scottish Enterprise would invest in the plant. Scottish Enterprise’s contribution is expected to be through a series of grants totalling £10-20 million to enable Valneva to commence production at the plant. Discussions between the Company and the Scottish Government also include potential supply of VLA2001 for Scotland in the future, subject to regulatory approval. Valneva has also offered to make up to 25,000 doses of VLA2001 available for primary immunisation, free of charge, to National Health Service and frontline workers in Scotland, subject to regulatory approval. The grant is subject to contract and final due diligence and is expected to include commitments to jobs for the future in Livingston. Commenting, David Lawrence, Acting Chief Financial Officer, said “We’re pleased that we’ve been able to advance discussions with Scottish Enterprise quickly, following the UK Government’s unexpected decision to terminate our supply agreement with them. We’ve reported excellent Phase 3 data and homologous booster data in the past couple of months, underlining the potential importance of VLA2001 – our inactivated, adjuvanted whole virus vaccine. Subject to regulatory approval we want to make VLA2001 available to people who need it, as soon as we can. We already have some vaccine stock available for distribution, upon approval. The grant will be very welcome and, subject to contract, will ensure that Livingston becomes a strategic vaccine manufacturing site for the future, successfully completing the work we began with HMG”. Ivan McKee, Scottish Government Minister for Business, Trade, Tourism and Enterprise, said “Valneva is a valued contributor to our life sciences sector and the Livingston facility is an important asset, developing vaccines for the treatment of several important infectious diseases and supporting high quality jobs. Ministers and Scottish Enterprise are in advanced discussions with the company to agree a package of support which would underpin the company’s operations in Scotland.” Hannah Bardell, MP for Livingston, added “I am delighted that the Scottish Government and Scottish Enterprise have listened to my constituency colleagues and I by agreeing to invest in Valneva’s vaccine manufacturing site in Livingston. This funding will enable Valneva to complete its expansion, boosting vital production capacity and protecting skilled jobs. It has been a pleasure to work with all involved in securing this agreement and I can only hope the UK Government will see the faith that we in Scotland have in Valneva.” Valneva is continuing to try to reach an amicable resolution with HMG regarding its termination of the supply agreement and performance of the ongoing clinical trial agreement. The Company continues to reserve all rights in the event that an amicable outcome is not achieved. About VLA2001 VLA2001 is currently the only whole virus, inactivated, adjuvanted vaccine candidate against COVID-19 in clinical trials in Europe. It is intended for active immunization of at-risk populations to prevent carriage and symptomatic infection with COVID-19 during the ongoing pandemic and potentially later for routine vaccination including addressing new variants. VLA2001 may also be suited for boosting, as repeat booster vaccinations have been shown to work well with whole virus inactivated vaccines. VLA2001 is produced on Valneva’s established Vero-cell platform, leveraging the manufacturing technology for Valneva’s licensed Japanese encephalitis vaccine, IXIARO®. VLA2001 consists of inactivated whole virus particles of SARS-CoV-2 with high S-protein density, in combination with two adjuvants, alum and CpG 1018. This adjuvant combination has consistently induced higher antibody levels in preclinical experiments than alum-only formulations and shown a shift of the immune response towards Th1. CpG 1018 adjuvant, supplied by Dynavax Technologies Corporation (Nasdaq: DVAX), is a component of the US FDA- and EMA-approved HEPLISAV-B® vaccine. About Valneva SE Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The Company takes a highly specialized and targeted approach to vaccine development and then applies its deep understanding of vaccine science to develop prophylactic vaccines addressing these diseases. Valneva has leveraged its expertise and capabilities both to successfully commercialize two vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus and COVID-19.

Read More

GOVERNMENT FINANCE

Tyler Technologies Extends 17-Year Relationship for Digital Government and Payment Solutions in the State of Colorado

Tyler Technologies | January 05, 2022

Tyler Technologies, Inc. today announced that the Colorado Statewide Internet Portal Authority (SIPA), on behalf of the state of Colorado, has signed a contract extension for Tyler’s award-winning digital government and payments services. The one-year agreement extends the existing 17-year relationship between Colorado’s SIPA and Tyler’s subsidiary, NIC. In the state of Colorado, Tyler’s NIC Division currently provides more than 1,100 digital government services, working with 580 state and local government entities and securely processing more than 8 million transactions. Among those services is a multi-award-winning content management system hosting more than 400 websites for government partners, including the state’s official website, Colorado.gov. Additionally, Tyler recently signed a 10-year agreement with the Colorado Department of Regulatory Agencies (DORA), Division of Professions and Occupations, for Tyler’s ETK Regulatory™ solution, its Socrata® insights solution for analytics, its mobile inspection solution, and NIC Payments™, an electronic payment solution. “The solutions we provide across the state of Colorado create smarter, safer, and stronger communities and meet residents’ growing demand for access to convenient, easy-to-use, and secure digital services,” said Elizabeth Proudfit, president of Tyler’s NIC Division. “We are thrilled to extend this trusted partnership and look forward to continuing to empower state and local governments in Colorado to drive impactful digital transformation.” About Tyler Technologies and NIC Acquired by Tyler Technologies on April 21, 2021, NIC is a leader in digital government solutions and payments, partnering with government to deliver user-friendly digital services that make it easier and more efficient to interact with government. NIC and Tyler are united in their mission to empower public sector entities to operate more efficiently and connect more transparently with their constituents and with each other. Tyler has more than 37,000 successful installations across more than 12,000 locations, with clients in all 50 states, Canada, the Caribbean, Australia, and other international locations. Tyler has been named to Government Technology's GovTech 100 list five times and has been recognized three times on Forbes' "Most Innovative Growth Companies" list.

Read More

GOVERNMENT FINANCE

Xlear Files Legal Response to Government’s Lawsuit

Xlear | December 23, 2021

Today, Xlear Inc. filed the company’s response to a Department of Justice lawsuit alleging violations of the Federal Trade Commission Act, among other allegations. The company denied all the Government’s allegations and leveled a series of affirmative defenses at the Government, including violations of Xlear’s First Amendment right to free speech. Nathan Jones, Xlear’s CEO, issued this statement regarding Xlear’s Response: The United States faces an already raging pandemic and yet another new, wildfire Omicron variant, which studies show is more transmissible, vaccine resistant and as severe as other strains. As a result, across the nation new cases are spiking and breaking records; hospitals are once again overflowing; schools are closing again; not only are we seeing breakthrough infections—we are facing reinfections; the NFL and the NHL have been forced to postpone games; and, there is a real risk that our lives and economy will once again have to close. It’s another COVID-Christmas in America. The nation’s vaccine-only strategy is failing. Despite this, the Federal Government continues to refuse to even discuss or consider other possible countermeasures—even though they are backed by sound science. Xlear’s Response outlines a series of studies, including two randomized clinical trials (RCTs)* and other clinical and lab data, that more than substantiate Xlear’s statements regarding COVID-19. One recent RCT study found that the use of nasal hygiene in treating COVID-19-infected people over the age of 50 reduced the risk of hospitalization 8-fold.** The Government hasn’t meaningfully challenged the legitimacy of these studies—the Government can’t, they paid for some of them and have published some of them. Nor has the Government offered conflicting studies—they can’t. The Government has known about these other countermeasures since June 2020. Yet, the Government still refuses to even discuss or consider them. The Response we filed also includes a new in vitro study done at Utah State University’s Institute for Antiviral Research.*** This new in vitro study (using human airway tissue) found that the components in Xlear were significantly more effective antivirals against the Delta strain of COVID-19 than Remdesivir, the Government-approved antiviral medicine. Ironically, the Government alleges it is Xlear that has misled the public. Not only is the Government refusing to consider other countermeasures, the Government, through this lawsuit, has sought to censor us from informing the American people about the science. The American people have both the right and the need to know the science. We hope this lawsuit serves as a vehicle to inform the public, as well as expose the abject failures of our Government in responding to this pandemic.

Read More

GOVERNMENT BUSINESS

Veteran-Owned Startup Awarded Multi-Year Federal Task Order for Cybersecurity

Aquia Inc | January 04, 2022

Aquia Inc., a Service-Disabled Veteran-Owned Small Business specializing in cloud and cybersecurity professional services, announced today that it has joined the RevaComm team on a five-year contract with Government Services Administration (GSA) supporting the Centers for Medicare and Medicaid Services (CMS) for the Office of Information Technology's Continuous Authorization and Verification Engine (batCAVE) initiative. CMS is the largest agency in the federal government by expenditure and is responsible for the personally identifiable and personal health information for more than 177 million people. In partnership with RevaComm, Aquia will develop and lead the following programs for CMS: Platform Security: Aquia is responsible for security engineering and architecture in support of batCAVE Platform-as-a-Service (PaaS) development, including guardrail development & integration, Continuous Integration/Continuous Deployment (CI/CD) & pipeline security, and development of DevSecOps tooling & automation. These efforts will help to shift security left and ensure the security and compliance of cloud-based application environments for CMS Application Development Organizations (ADO)'s. Purple Team: Aquia will be providing joint offensive (Red) and defensive (Blue) cybersecurity capabilities, otherwise known as a Purple Team. This team will be focused on identifying, exploiting and remediating security vulnerabilities related to the batCAVE platform, ensuring a robust and resilient platform for CMS stakeholders. Compliance Automation: Aquia will use innovative technology to support and foster a culture of Continuous Compliance and Governance with the goal of moving towards a Continuous Authority-to-Operate (cATO) for batCAVE platform. David Maskeroni, Aquia's Chief Executive Officer, had this to say when discussing the batCAVE initiative, "This is a great opportunity to bring cloud-based application delivery to the Federal Civilian government, with security baked into the very heart of the initiative. We are very proud to be a critical member of this team." About Aquia Inc. Aquia Inc. is a Service-Disabled Veteran-Owned Small Business based in Millsboro, DE. Aquia is a developer-centric company founded in 2021 by military veterans with passion for the intersection of security/velocity and decades of experience driving transformational change across public sector, enterprise and top-tier technology companies. At Aquia, we value trust, accountability, transparency and diversity; and we've built these tenants into the DNA of our company.

Read More

Spotlight

The Hamilton Project seeks to advance America’s promise of opportunity, prosperity, and growth. We believe that today’s increasingly competitive global economy demands public policy ideas commensurate with the challenges of the 21st Century. The Project’s economic strategy reflects a judgment that long-term prosperity is best achieved by fostering economic growth and broad participation in that growth, by enhancing individual economic security, and by embracing a role for effective government in making needed public investments.

Resources